CLSI M100 S21 : 21ED 2010

Abstract
Committee Membership
Summary of Major Changes in this Document
Summary of CLSI Processes for Establishing Interpretive
Criteria and QC Ranges
CLSI References Methods vs Commercial Methods and CLSI
vs FDA Breakpoints
Subcommittee on Antimicrobial Susceptibility Testing
Mission Statement
Introduction to Table 1 and 2 for Use With M02-A10 (Disk
Diffusion) and M07-A8 (MIC Testing)
Appendix A - Suggestions for Confirmation of Resistant (R),
             Intermediate (I), or Nonsuscepitble (NS)
             Antimicrobial Susceptibility Test Results and
             Organism Identification
Appendix B - Intrinsic Resistance - Enterobacteriaceae
Appendix C - Quality Control Strains for Antimicrobial
             Susceptibility Tests
Appendix D - Cumulative Antimicrobial Susceptibility Report
             for Bacteroides fragilis Group Organisms
Appendix E - Cumulative Antimicrobial Suscepribility Report
             for Anaerobic Organisms Other Than Bacteroides
             fragilis group
Glossary I (Part 1) - Beta-lactams: Class and Subclass
                      Designation and Generic Name
Glossary I (Part 2) - Non-Beta-lactams: Class and Subclass
                      Designation and Generic Name
Glossary II - Abbreviations/Routes of Administration/Drug Class
              for Antimicrobial Agents Listed in M100-S21
Glossary III - List of Identical Abbreviations Used for More
               Than One Antimicrobial Agents in US Diagnostic
               Products
Summary of Comments and Subcommittee Responses
The Quality Management System Approach
Related CLSI References Materials